NextGenNK is a Competence Center for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Vinnova, KI, and the Industrial partners.
Dr. Rizwan Romee visit to NextGenNK
Dr. Rizwan Romee, Dana-Farber Cancer Institute, visited NextGenNK August 21-22. During the visit Dr. Romee presented his work within the NK cell field and interacted with researchers and partners within NextGenNK. Photo: Quirin Hammer
XNK one of three winners of Business Sweden’s Catalyst program 2023
NextGenNK congratulates XNK Therapeutics for being selected as one of three winners of Business Sweden’s Catalyst program 2023. The program identifies Swedish companies having the strongest prerequisites to scale up globally.
Article: Natural Killer cells are tested against hematological cancer
Ebba Sohlberg, a senior researcher in NextGenNK, was recently interviewed by Dagens Medicin, Sweden's leading newspaper in the healthcare sector. The interview centered around NK cell therapy, the team's utilization of 'superdonors' in the development of their new allogeneic cell therapy based on adaptive NK cells, as well as their upcoming clinical studies focusing on hematological cancer (Article in Swedish). Photo: Erik Wetterskog
Awards and recognitions
NextGenNK at Innate Killer Summit 2023
co-leader Evren Alici was selected as one of the world-class speakers at Innate Killer Summit 2023.
Arnika Wagner - KID funding
Arnika Wagner, assistant professor at Karolinska Institutet, was granted KID funding for a new PhD student.
Nutsa Burduli - Best Oral Presentation
Nutsa Burduli, PhD student at Karolinska Institutet was awarded Best Oral Presentation at Tissue & Motion Conference 2022, Djurönäset, Sweden.
Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
Haroun-Izquierdo A. et al, J Immunother Cancer, 2022
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH et al, Cancer Immunol Immunother, 2022
A tractable microscopy- and flow cytometry-based method to measure natural killer cell-mediated killing and infiltration of tumor spheroids
Schwietzer et al, Methods in Cell Biology, 2022